SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 16 Aug 2025, 03:15 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]](https://i.ytimg.com/vi/4BpQ2UngdZY/hqdefault.jpg)
AI-generated source summary
The analysis assesses XBI, an ETF holding several positive signals with a strong rising trend. The system ranks it as a strong buy candidate, a score of 7.3 as of August 15, 2025. Since August 12, 2025, the ETF has gained 4.33%, an average of 1.08% daily. Current analysis suggests a potential 10.29% increase in the next three months. Expected returns range from 4.25% to 11.87%. However, the 12-month analysis projects a potential decline of approximately 19.18%. A short term perspective shows a potential price range between 50.20 to 73.29. The latest daily update for XBI highlights, upgraded to a strong buy candidate after a recent increase. The recent day has risen by 1.24% which translates from 89.57 to 90.68. The ETF's 52 week high indicates 105.47. Positive signals included both short and long-term moving averages, as per volume analysis trading levels can find support at 87.51 and 86.44.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
